title: Chemotherapy does not influence intestinal amino acid uptake in children.
abstract: Chemotherapy will frequently induce intestinal damage (mucositis). Enteral nutrition is then often withheld for fear of impaired intestinal absorption as shown in animal models. There is no clinical evidence, however, that absorption is indeed compromised during chemotherapy-induced mucositis. The aim of this study was to evaluate systemic availability of dietary amino acids (leucine) during chemotherapy-induced mucositis. We studied eight childhood cancer patients (age 1.5-16 y) on 2 d, i.e. the day before chemotherapy and 3-5 d after. Chemotherapy-induced oral mucositis and diarrhea were scored on a World Health Organization toxicity scale. Stable isotope tracers were used to measure first-pass splanchnic leucine uptake and whole-body leucine kinetics. Patients showed increased mucositis and/or diarrhea toxicity scores (p < 0.0001) after chemotherapy. Systemic availability of enterally administered leucine was not significantly affected by chemotherapy (before 60%, after 90%, p = 0.46). Interestingly, five patients already showed a negative leucine balance before chemotherapy. In conclusion, most children receiving chemotherapy are already catabolic before start of a new cycle of chemotherapy. Amino acid transport as measured by leucine uptake in the intestine is not affected by chemotherapy-induced mucositis.
authors.affiliation: Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, 3015GJ Rotterdam, the Netherlands.
authors.forename: Barbara A
authors.initials: BA
authors.lastname: de Koning
authors.forename: Sophie R
authors.initials: SR
authors.lastname: van der Schoor
authors.forename: Darcos L
authors.initials: DL
authors.lastname: Wattimena
authors.forename: Peter C
authors.initials: PC
authors.lastname: de Laat
authors.forename: Rob
authors.initials: R
authors.lastname: Pieters
authors.forename: Johannes B
authors.initials: JB
authors.lastname: van Goudoever
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001944:Breath Tests; D002245:Carbon Dioxide / Q000378:metabolism; D002247:Carbon Isotopes; D002648:Child; D002675:Child, Preschool; D003967:Diarrhea / Q000139:chemically induced* / Q000378:metabolism; D004750:Enteral Nutrition; D006801:Humans; D007223:Infant; D007408:Intestinal Absorption; D007930:Leucine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D012720:Severity of Illness Index; D013152:Splanchnic Circulation; D013280:Stomatitis / Q000139:chemically induced* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D002247:Carbon Isotopes; D002245:Carbon Dioxide; D007930:Leucine